Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 122889-11-6 | MDL No. : | MFCD00237032 |
Formula : | C25H23NO5 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | DYBDGLCDMLNEMJ-HSZRJFAPSA-N |
M.W : | 417.45 | Pubchem ID : | 7019719 |
Synonyms : |
|
Chemical Name : | Fmoc-D-Ser(Bzl)-OH |
Num. heavy atoms : | 31 |
Num. arom. heavy atoms : | 18 |
Fraction Csp3 : | 0.2 |
Num. rotatable bonds : | 10 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 115.55 |
TPSA : | 84.86 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | Yes |
CYP2D6 inhibitor : | Yes |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -5.99 cm/s |
Log Po/w (iLOGP) : | 2.74 |
Log Po/w (XLOGP3) : | 4.03 |
Log Po/w (WLOGP) : | 4.04 |
Log Po/w (MLOGP) : | 2.82 |
Log Po/w (SILICOS-IT) : | 3.98 |
Consensus Log Po/w : | 3.52 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -4.74 |
Solubility : | 0.00765 mg/ml ; 0.0000183 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -5.52 |
Solubility : | 0.00127 mg/ml ; 0.00000305 mol/l |
Class : | Moderately soluble |
Log S (SILICOS-IT) : | -7.5 |
Solubility : | 0.0000133 mg/ml ; 0.0000000318 mol/l |
Class : | Poorly soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 3.0 |
Synthetic accessibility : | 4.31 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
77% | With sulfuric acid; In dichloromethane; at 0℃; | Example 9. N- [ (9H-Fluoren-9-vl) methoxvcarbonyl]-O- (benzyl)-D-serine t-Butyl ester. N- [ (9H-Fluoren-9-yl) methoxycarbonyl]-O- (benzyl)-D-serine (0.710 g, 1.70 mmole) in dichloromethane (8 mL) was treated with t-butyl acetate (3 mL) and concentrated sulfuric acid (40 1L) in a sealed flask at 0 °C. Upon completion (TLC), the reaction was quenched with of dichloromethane (10 mL) and saturated aqueous potassium bicarbonate (15 mL). The organic layer was washed with distilled water, and evaporated. The resulting residue was purified by flash column chromatography (98: 2 dichloromethane/methanol) to yield the title compound as a colorless oil (0.292 g, 77percent); lH NMR (CDC13) a 1.44 (s, 9H); 3.68 (dd, J = 2.9 Hz, J = 9.3 Hz, 1H); 3.87 (dd, J = 2.9 Hz, J = 9.3 Hz, 1H); 4.22 (t, J = 7.1 Hz, 1H); 4.30-4. 60 (m, 5H) ; 5.64-5. 67 (m, 1H); 7.25- 7.39 (m, 9H); 7.58-7. 61 (m, 2H); 7.73-7. 76 (m, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Chelmical synthesis: Peptides were synthesized on a Rink amide resin, 0.45 mmol/g [Fmoc-Cys(Trityl)-Wang; Novabiochem, San Diego, Calif.] usinig N-(9-fluorenyl)methoxycarboxyl chemistry and standard side chain protection except on cysteine residues. Cysteine residues were protected in pairs with either S-trityl on the first and third cysteines or S-acetamidomethyl on the second and fourth cysteines. Amino acid derivatives were from Advanced Chemtech (Louisville, Ky.). The peptides were removed from the resin and precipitated, and a two-step oxidation protocol was used to selectively fold the peptides as described previously (Luo et al., 1999). Briefly, the first disulfide bridge was closed by dripping the peptide into an equal volume of 20 mM potassium feliicyanide and 0.1 M Tris, pH 7.5. The solution was allowed to react for 30 min, and the monocyclic peptide was purified by reverse-phase HPLC. Simultaneous removal of the S-acetamidomethyl groups and closure of the second disulfide bridge was carried out by iodine oxidation. The monocyclic peptide and HPLC eluent was dripped into an equal volume of iodine (10 mM) in H20/trifluoroacetic acid/acetonitrile (78:2:20 by volume) and allowed to react for 10 min. The reaction was terminated by the addition of ascorbic acid diluted 20-fold with 0.1percent trifluoroacetic acid and the bicyclic product purified by HPLC. Mass Spectrometry: Measurements were performed at the Salk Institute for Biological Studies (San Diego, Calif.) under the direction of Jean Rivier. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and liquid secondary ionization mass spectrometry were used. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Steps 3 through 6 were then repeated with the following order of amino acids:Fmoc-Cys(Acm)Fmoc-Ser(Bzl)Fmoc-Gly |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
79% | General procedure: The peptides were synthesized on an activated [44] 2-chlorotrityl chloride resin (1 g) which had been swelled in dry DCM for 30 min. The first Fmoc amino acid (4 equiv) was coupled to the resin manually using dry DCM (10 mL) and DIPEA (6 equiv) for 2 h under a N2 atmosphere. Resin substitution was then determined using the Fmoc UV assay. On 0.1 mM scale subsequent amino acids were also coupled manually using amino acid (0.20 mM, 2.5 mL), DIPEA (1 mM, 1.0 mL) and HBTU (0.50 mM, 1.0 mL) in DMF. The Fmoc group of amino acid was removed using 20percent piperidine?DMF (3 × 10 mL) for 30 min and the next amino acid and sugar amino acid 1a/b were coupled on resin using the same condition. The excess reagents were washed with DMF (2 × 7 mL) and DCM (2 × 7 mL). Cleavage from resin was performed manually, using a cleavage mixture of TFA?DCM [5:95percent (v/v), 3 × 10 mL] for 30 min. The crude compound was then purified using semi-preparative HPLC. All compounds were obtained in good yields. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
80% | General procedure: The peptides were synthesized on an activated [44] 2-chlorotrityl chloride resin (1 g) which had been swelled in dry DCM for 30 min. The first Fmoc amino acid (4 equiv) was coupled to the resin manually using dry DCM (10 mL) and DIPEA (6 equiv) for 2 h under a N2 atmosphere. Resin substitution was then determined using the Fmoc UV assay. On 0.1 mM scale subsequent amino acids were also coupled manually using amino acid (0.20 mM, 2.5 mL), DIPEA (1 mM, 1.0 mL) and HBTU (0.50 mM, 1.0 mL) in DMF. The Fmoc group of amino acid was removed using 20percent piperidine?DMF (3 × 10 mL) for 30 min and the next amino acid and sugar amino acid 1a/b were coupled on resin using the same condition. The excess reagents were washed with DMF (2 × 7 mL) and DCM (2 × 7 mL). Cleavage from resin was performed manually, using a cleavage mixture of TFA?DCM [5:95percent (v/v), 3 × 10 mL] for 30 min. The crude compound was then purified using semi-preparative HPLC. All compounds were obtained in good yields. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
79% | With 1-hydroxybenzotriazol-hydrate; dicyclohexyl-carbodiimide; In N,N-dimethyl-formamide; at 20℃; for 24h; | General procedure: To a stirred solution of the appropriate amino beta-lactam 10 or 11 (4.76 mmol) in anhydrous DMF (30 mL) were added DCC (5.7 mmol), Cbz- or Fmoc-protected l-amino acid (5.7 mmol) and HOBt.H2O (7.3 mmol) at room temperature. After 24 hours, ethyl acetate (50 mL) was added and the mixture was filtered. DMF was removed by washing with water (5 × 50 mL). The organic layer containing the product was reduced in vacuo. The product was isolated by flash column chromatography (dichlormethane: methanol gradient).#10;#10; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | With 1-hydroxybenzotriazol-hydrate; dicyclohexyl-carbodiimide; In N,N-dimethyl-formamide; at 20℃; for 24h; | General procedure: To a stirred solution of the appropriate amino beta-lactam 10 or 11 (4.76 mmol) in anhydrous DMF (30 mL) were added DCC (5.7 mmol), Cbz- or Fmoc-protected l-amino acid (5.7 mmol) and HOBt.H2O (7.3 mmol) at room temperature. After 24 hours, ethyl acetate (50 mL) was added and the mixture was filtered. DMF was removed by washing with water (5 × 50 mL). The organic layer containing the product was reduced in vacuo. The product was isolated by flash column chromatography (dichlormethane: methanol gradient).#10;#10; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
85% | With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;Inert atmosphere; | Amino acid S30 (27 mg, 0.065 mmol) and S31 (10 mg, 0.0599 mmol) were dissolved in 0.6 mL dry DMF, followed by addition of HATU (30mg, 0.077mmol), DIPEA (25|xL 0.1797 mmol). The resulting mixture was stirred under room temperature overnight and diluted with EtOAc. The solution was washed with 1M HCl and a saturated aqueous NaHCO3 solution. The combined organic phase was dried over Na2SO4 and concentrated, purified by silica gel column to afford compound S32 (27 mg, 85percent). |
[ 159610-93-2 ]
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxypropanoic acid
Similarity: 0.94